Jan 14, 2026 07:53AM Monte Rosa Therapeutics (GLUE) PT Raised to $37 at Piper Sandler

Jan 7, 2026 02:25PM Monte Rosa Therapeutics (GLUE) PT Raised to $31 at Jefferies

Jan 7, 2026 02:25PM TD Cowen on Monte Rosa Therapeutics (GLUE): 'the overall database shows little of concern'

Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026

Dec 17, 2025 04:28AM Monte Rosa Therapeutics (GLUE) PT Raised to $22 at Jefferies

Dec 16, 2025 10:38AM Monte Rosa Therapeutics (GLUE) PT Raised to $26 at Wedbush

Dec 16, 2025 07:01AM Monte Rosa reports positive results for prostate cancer drug combo

Dec 16, 2025 06:03AM Wells Fargo Upgrades Monte Rosa Therapeutics (GLUE) to Overweight

Nov 10, 2025 02:33AM Monte Rosa presents preclinical data on MRT-8102 at AHA sessions

Nov 6, 2025 07:06AM Monte Rosa Therapeutics, Inc. (GLUE) reported Q3 Revenue

Oct 24, 2025 07:00AM Monte Rosa presents preclinical data on MRT-6160 for autoimmune diseases

Sep 15, 2025 12:02PM TD Cowen Reiterates Buy Rating on Monte Rosa Therapeutics (GLUE) Following Expanded Novartis Deal

Sep 15, 2025 08:16AM Monte Rosa surges premarket on Novartis collaboration deal

Sep 15, 2025 07:01AM Monte Rosa secures $120 million Novartis deal for immune disease drugs

Aug 7, 2025 07:04AM Monte Rosa Therapeutics, Inc. (GLUE) reported Q2 Revenue

Jun 10, 2025 07:00AM Monte Rosa Therapeutics (GLUE) Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

May 8, 2025 07:05AM Monte Rosa Therapeutics, Inc. (GLUE) reported Q1 Revenue

Apr 28, 2025 07:05AM Monte Rosa Therapeutics (GLUE) Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat H

Mar 20, 2025 09:39AM Monte Rosa Therapeutics (GLUE) Files $400M Mixed Shelf

Mar 20, 2025 07:04AM Monte Rosa Therapeutics, Inc. (GLUE) reported Q4 Revenue

Jan 10, 2025 07:05AM Monte Rosa Therapeutics (GLUE) Provides Corporate Update and Key Anticipated Milestones for 2025

Dec 13, 2024 07:00AM Monte Rosa Therapeutics (GLUE) Appoints Dr. Eric A. Hughes to Board of Directors

Dec 11, 2024 07:02AM Monte Rosa Therapeutics (GLUE) Presents Preclinical Data

Dec 5, 2024 07:04AM Monte Rosa Therapeutics (GLUE) Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Nov 7, 2024 07:23AM Monte Rosa Therapeutics, Inc. (GLUE) Tops Q3 EPS by 18c

Nov 7, 2024 07:05AM Monte Rosa Therapeutics, Inc. (GLUE) Tops Q3 EPS by 18c

Oct 28, 2024 02:06PM Monte Rosa Therapeutics (GLUE) options active on 11K contracts with a focus on November 5, 7.5 and 10 puts as share price up 128%

Oct 28, 2024 12:25PM TD Cowen Reiterates Buy Rating on Monte Rosa Therapeutics (GLUE)

Oct 28, 2024 07:01AM Monte Rosa Therapeutics (GLUE) Announces Global License Agreement with Novartis (NVS) to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Oct 23, 2024 07:07AM Monte Rosa Therapeutics (GLUE) Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified S

Aug 19, 2024 07:01AM Monte Rosa Therapeutics (GLUE) Announces First Participants Dosed in MRT-6160 Phase 1 Study

Aug 8, 2024 07:13AM Monte Rosa Therapeutics, Inc. (GLUE) Tops Q2 EPS by 10c

Jun 28, 2024 10:41AM TD Cowen Reiterates Buy Rating on Monte Rosa Therapeutics (GLUE)

Jun 28, 2024 07:55AM Piper Sandler Reiterates Overweight Rating on Monte Rosa Therapeutics (GLUE)

Jun 27, 2024 07:06AM Monte Rosa Therapeutics (GLUE) Provides Development Progress Updates on MRT-2359 and MRT-6160

Jun 17, 2024 08:10AM Piper Sandler Reiterates Overweight Rating on Monte Rosa Therapeutics (GLUE)

Jun 14, 2024 08:46AM Monte Rosa Therapeutics (GLUE) Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis